Breaking News, Financial News

Financial Report: Hospira 4Q

Growth in the quarter was driven by an increase in Specialty Injectable Pharmaceuticals, with sales in the Americas up 27% to $439.2 million, in Europe, Middle East & Africa, sales were $76.7 million (+21%), and in the Asia Pacific region, sales were

Hospira 4Q

4Q Revenues: $1.1 billion (+16%)

4Q Earnings: $97.0 million (-8%)

FY Revenues: $3.9 billion (+7%)

FY Earnings: $403.9 million (+26%)

Comments: Growth in the quarter was driven by an increase in Specialty Injectable Pharmaceuticals, with sales in the Americas up 27% to $439.2 million, in Europe, Middle East & Africa, sales were $76.7 million (+21%), and in the Asia Pacific region, sales were $62.4 million (+25%). The company launched the generic chemotherapy agent oxaliplatin in the U.S. and sales of the sedation agent Precedex, continued to grow.

Click here to find out more about Hospira

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters